Evolus Stock Price, News & Analysis

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of stock options and restricted stock units (RSUs) to newly hired employees. The company granted:

- Non-qualified stock options to purchase 10,251 shares and 31,049 RSUs to 16 new non-executive employees

- Individually negotiated awards to Umberto La Magna, Senior VP, International, including options to purchase 40,286 shares and 28,213 RSUs

These awards, approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, have a grant and vesting commencement date of October 7, 2024. The stock options have an exercise price of $16.49 per share, a 10-year term, and vest over 4 years with 25% vesting annually. RSUs also vest 25% annually over 4 years.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has reported the grant of 10,845 restricted stock units (RSUs) to 5 newly hired non-executive employees. The awards were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date of September 12, 2024, and a vesting commencement date of September 7, 2024.

The RSUs are designed to vest 25% on each annual anniversary of the vesting commencement date. These grants serve as an inducement for new employees joining Evolus, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the RSU agreement, including continuous employment requirements on each vesting date.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will ring the Nasdaq closing bell on Friday, September 13, 2024. The ceremony, taking place at the Nasdaq MarketSite in Times Square, New York City, will be led by CEO David Moatazedi and the company's leadership team. This event celebrates Evolus' five-year anniversary as a publicly traded company and follows their recent investor day on September 12th.

Moatazedi highlighted the company's transformation from a single-product aesthetics company to a multi-product performance beauty innovator. The live broadcast of the ceremony will begin at 3:45 p.m. Eastern Time, and management will participate in a Behind the Bell interview before the event.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of restricted stock units (RSUs) and stock options to newly hired non-executive employees. In July, 46,363 RSUs were granted to 16 employees. In August, 35,921 RSUs and options to purchase 18,097 shares were granted to 10 employees. The August stock options have an exercise price of $12.91 per share and a 10-year term. Both RSUs and options vest over 4 years, with 25% vesting annually. These grants were approved under Evolus' 2023 Inducement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for new employees.

Evolus (NASDAQ: EOLS) reported strong Q2 2024 results, with total net revenue of $66.9 million, up 36% year-over-year. The company raised its full-year 2024 net revenue guidance to $260-$270 million, representing up to 34% growth. Evolus achieved its first-ever quarter of profitability with positive non-GAAP operating income of $1.1 million. Key highlights include:

- Added 770 new customer accounts, totaling ~14,000 since launch
- Evolus Rewards program grew to over 900,000 members
- Submitted PMA application to FDA for Evolysse™ Lift and Smooth fillers
- Launched Nuceiva® in Spain
- Expects approval and launch of fillers in H2 2025
- Projects total net revenue to reach at least $700 million by 2028

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has announced its upcoming Investor Day scheduled for September 12, 2024 in New York City. The event will be held at the "SECOND Floor" venue and will offer both in-person and webcast participation options. Starting at 7:30 a.m. ET with breakfast, formal presentations will begin at 8:00 a.m. ET and conclude by 12:00 p.m. ET.

During the event, Evolus' management team will provide detailed insights into the company's strategic vision, investment strategies, growth levers, and financial outlook. The presentations will be followed by a Q&A session. Pre-registration is required for both in-person and webcast attendees. A replay of the webcast and supporting materials will be made available on the Evolus website after the event.

Evolus, Inc. (NASDAQ: EOLS) has launched Nuceiva® (prabotulinumtoxinA) in Australia, expanding its global footprint in the aesthetic market. This strategic move is part of the company's geographic expansion strategy, with Evolus Australia established to drive medical education, training, marketing, and sales to healthcare professionals in the medical aesthetics field.

Nuceiva® is approved by the Therapeutic Goods Administration (TGA) for temporarily improving the appearance of moderate to severe glabellar lines in adult patients. The product, known as Jeuveau® in the United States, has been the fastest-growing neurotoxin in the U.S. for three consecutive years. Evolus aims to offer this new treatment to patients by working closely with aesthetics healthcare professionals in Australia.

The company's expansion into Australia is led by Daniel Henry, with support from Dan Stewart, Vice President and General Manager of Evolus International. This launch is expected to fuel Evolus' global growth strategy and reinforce its position as a global leader in the aesthetics industry.

Evolus (NASDAQ: EOLS), a performance beauty company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. Sandra Beaver, CFO of Evolus, will present at the event on Tuesday, August 13, 2024, from 12:30 – 12:55 PM ET.

The presentation will take the form of a fireside chat, which will be accessible to investors via a webcast on the Investor Relations page of the Evolus website. For those unable to attend live, a replay of the webcast will be available for 90 days following the presentation, providing ample opportunity for investors to gain insights into the company's growth strategies and performance.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has announced it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET the same day to discuss the results, followed by a Q&A session.

Interested parties can participate in the conference call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or by connecting to the live webcast on the Investor Relations page of the Evolus website. A telephonic replay will be available after the call, and an archived webcast can be accessed on the company's website.